Emergent BioSolutions (NYSE:EBS) Downgraded to Hold Rating by StockNews.com

StockNews.com lowered shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a research note released on Saturday morning.

EBS has been the subject of several other reports. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark raised their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Stock Performance

Shares of NYSE EBS opened at $8.27 on Friday. Emergent BioSolutions has a 12-month low of $1.42 and a 12-month high of $15.10. The firm has a market capitalization of $448.10 million, a price-to-earnings ratio of -2.02 and a beta of 1.59. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The firm has a 50 day moving average of $9.21 and a 200 day moving average of $8.87.

Hedge Funds Weigh In On Emergent BioSolutions

Several hedge funds have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. bought a new stake in shares of Emergent BioSolutions during the 2nd quarter worth approximately $41,000. Verus Capital Partners LLC bought a new stake in shares of Emergent BioSolutions during the second quarter worth $68,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Emergent BioSolutions during the second quarter valued at $93,000. Stifel Financial Corp bought a new position in shares of Emergent BioSolutions in the third quarter worth about $96,000. Finally, Morse Asset Management Inc bought a new position in shares of Emergent BioSolutions in the second quarter worth about $97,000. 78.40% of the stock is currently owned by institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.